Phenomenon of individual difference in human monocyte activation

Experimental and Molecular Pathology

Volumn 99, Issue 1, 2015, Pages 151-154

  Orekhov, Alexander N ^a,b,c   Nikiforov, Nikita G ^a,c   Elizova, Natalia V ^a,c   Ivanova, Ekaterina A ^d   Makeev, Vsevolod J ^e  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c Institute for Atherosclerosis Research   (Russian Federation)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

Author keywords

Activation; Cholesterol; Cytokine; Individual profile; Monocyte

Indexed keywords

ARTICLE; ASYMPTOMATIC DISEASE; BLOOD CELL; CAROTID ATHEROSCLEROSIS; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE FUNCTION; MONOCYTE; PHENOMENOLOGY; ARTERIAL WALL THICKNESS; CAROTID ARTERY DISEASE; CD4+ T LYMPHOCYTE; DISEASE COURSE; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; METABOLISM; PATHOLOGY;

BETA CHEMOKINE; CCL18 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; MACROPHAGES; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934937360     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.06.011     Document Type: Article

References (14)

1. De Paoli F., et al. Macrophage phenotypes and their modulation in atherosclerosis. Circ. J. 2014, 78:1775-1781.
2. Gaudreault N., et al. ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 2012, 32:264-272.
3. Gerrity R.G. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am. J. Pathol. 1981, 103:191-200.
4. Hansson G.K., et al. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1714-1717.
5. Libby P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2045-2051.
6. Libby P., et al. Transatlantic network on atherothrombosis: inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54:2129-2138.
7. Orekhov A.N., et al. Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis 1991, 86:153-161.
8. Orekhov A.N., et al. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. Int. J. Mol. Sci. 2014, 15:12807-12841.
9. Querfeld U., et al. Lipid levels in monocytes of patients with moderate hyperlipoproteinemia. Atherosclerosis 1992, 94:129-134.
10. Shapiro S.S., Wilk M.B. An analysis of variance test for normality (complete samples). Biometrika 1965, 52:591-611.
11. Tertov V.V., et al. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem. Biophys. Res. Commun. 1990, 167:1122-1127.
12. Tertov V.V., et al. Lipid-laden white blood cells in the circulation of patients with coronary heart disease. Exp. Mol. Pathol. 1992, 57:22-28.
13. Tertov V.V., et al. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp. Mol. Pathol. 1995, 62:166-172.
14. Wilk M.B., Gnanadesikan R. Probability plotting methods for the analysis of data. Biometrika 1968, 55:1-17.